Overactive Bladder - Results from #2220

EAU 2012 - The β3-adrenoceptor agonist Solabegron is safe and effective for improving symptoms of overactive bladder - Session Highlights March 30, 2012

EAU 2012 - Health-related quality of life in patients with overactive bladder - Session Highlights March 30, 2012

EAU 2012 - Effect of treatment response on the decision to escalate antimuscarinic dose in elderly subjects with overactive bladder - Session Highlights March 30, 2012

EAU 2012 - Prevalence and clinical features of detrusor underactivity among the community-dwelling elderly with lower urinary tract symptoms: A comparison between men and women - Session Highlights March 30, 2012

EAU 2012 - Value of nerve growth factor levels in overactive bladder syndrome – alterations after botulinum toxin therapy - Session Highlights March 30, 2012

EAU 2012 - The β3-adrenoceptor agonist Solabegron is safe and effective for improving symptoms of overactive bladder - Poster March 30, 2012

EAU 2012 - Urethral versus suprapubic catheter for patients with spinal cord injury induced neurogenic bladder: A study applying the eleven-year comprehensive nationwide database of Taiwan - Session Highlights March 30, 2012

EAU 2012 - Urodynamics practice workshop - Session Highlights March 30, 2012

EAU 2012 - Injecting DIGNITY into your neurogenic detrusor overactivity (NDO) patient treatment paradigm: The role of botulinum toxin type A - Session Highlights March 30, 2012

Etiology of overactive bladder: A diet and lifestyle model for diabetes and obesity in older women - Abstract March 28, 2012

An overview of treatment of overactive bladder syndrome in women - Abstract March 19, 2012

Impact of overactive bladder treatment on associated comorbidities - Abstract March 16, 2012

Standard pharmacological treatment and new therapies for overactive bladder - Abstract March 14, 2012

Contemporary management of overactive bladder - Abstract March 9, 2012

Pathophysiology of overactive bladder - Abstract March 7, 2012

Solifenacin for overactive bladder: A systematic review and meta-analysis - Abstract March 6, 2012

How does the urothelium affect bladder function in health and disease? - Abstract February 24, 2012

Physiopathology of overactive bladder syndrome - Abstract February 21, 2012

Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: Pooled analysis of two open-label extension studies - Abstract February 7, 2012

Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients - Abstract February 7, 2012

Page 112 of 122